Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) shares rose 14.5% on Tuesday . The company traded as high as $2.10 and last traded at $1.90. Approximately 973,830 shares changed hands during mid-day trading, an increase of 269% from the average daily volume of 264,067 shares. The stock had previously closed at $1.66.
CANF has been the topic of a number of recent research reports. Maxim Group set a $7.00 target price on Can Fite Biopharma and gave the stock a “buy” rating in a research note on Monday, December 18th. HC Wainwright restated a “buy” rating on shares of Can Fite Biopharma in a research note on Tuesday, October 31st.
The company has a market capitalization of $25.30, a P/E ratio of 6.24 and a beta of 1.37.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.